It’s official – Alfa Laval has opened its new premises in Flemingsberg!

The new 8,000 m² innovation center brings together 700 experts who push the boundaries of future solutions in energy, food, pharma and marine transport every day. An investment that truly shows how important Swedish industrial expertise, open collaborations and continued R&D are – not only for Alfa Laval, but for the whole of Europe.

And yes, you can now find them on Separatorvägen, a street that was recently renamed specifically to welcome Alfa Laval to the area. That’s how we do it in Flemingsberg. The building rises as a new, clear presence in the area and becomes a natural part of Flemingsberg’s growing skyline.

The innovation center was opened by Alfa Laval’s President and CEO Tom Erixon together with Sweden’s Minister for EU Affairs Jessica Rosencrantz.

We wish Alfa Laval a warm welcome to Flemingsberg!

Did you know that Alfa Laval also operates within life science? At their Flemingsberg site, the company develops and supplies advanced separation and fluid-handling technologies — including centrifuge separators and hygienic processing solutions — designed for demanding applications in both life-science (biotech, pharmaceuticals) and Food & Water (food processing, water treatment) sectors.

Portabel Health: Crowned Winner of Flemingsberg Science STARTUP Award 2025

Quickly finding the right personnel is one of the healthcare sector’s major challenges, especially in times of staff shortages and increasing demands for efficiency. Portabel Health offers a modern solution to these problems through a digital platform that makes it easy for care providers to access qualified nurses and healthcare professionals.

Press Start: The Game Hub in Flemingsberg – Finally!

On April 24th, after just two months of hard work, it was finally time for the kick-off for the game cluster Press Start. The initiative is led by Drivhuset, in close collaboration with Flemingsberg Science Foundation and Södertörn University's Innovation Station.

AlzeCure Pharma – a hope in the fight against Alzheimer’s

Neurological diseases and the pain area are struggling with great medical needs, including the lack of broad-spectrum drugs. Those are gaps in the market that AlzeCure Pharma wants to fill, and they are well on their way. They recently received a grant from the European Innovation Council (EIC) to finance a clinical phase 2 study of the drug candidate NeuroRestore ACD856 for Alzheimer’s disease.

Previous 121314 Next